These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23754483)

  • 1. [Breakthrough pain and short-acting opioids].
    Beutlhauser T; Oeltjenbruns J; Schäfer M
    Anaesthesist; 2013 Jun; 62(6):431-9. PubMed ID: 23754483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioids for the management of breakthrough pain in cancer patients.
    Zeppetella G; Davies AN
    Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-based treatment of cancer-related breakthrough pain with opioids.
    Zeppetella G
    J Natl Compr Canc Netw; 2013 Mar; 11 Suppl 1():S37-43. PubMed ID: 23520185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cancer breakthrough pain. Indications for rapidly effective opioids].
    Kessler J; Bardenheuer HJ
    Anaesthesist; 2011 Jul; 60(7):674-82. PubMed ID: 21491140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
    Elsner F; Zeppetella G; Porta-Sales J; Tagarro I
    Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fentanyl for breakthrough pain: a systematic review.
    Davis MP
    Expert Rev Neurother; 2011 Aug; 11(8):1197-216. PubMed ID: 21797660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and clinical differences among transmucosal fentanyl formulations for the treatment of breakthrough cancer pain: a review article.
    Corli O; Roberto A
    Minerva Anestesiol; 2014 Oct; 80(10):1123-34. PubMed ID: 24346227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
    Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
    Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fentanyl for the treatment of tumor-related breakthrough pain.
    Bornemann-Cimenti H; Wejbora M; Szilagyi IS; Sandner-Kiesling A
    Dtsch Arztebl Int; 2013 Apr; 110(16):271-7. PubMed ID: 23671467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WITHDRAWN: Opioids for the management of breakthrough pain in cancer patients.
    Zeppetella G; Davies AN
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD004311. PubMed ID: 26275024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.
    Mystakidou K; Katsouda E; Parpa E; Tsiatas ML; Vlahos L
    Am J Hosp Palliat Care; 2005; 22(3):228-32. PubMed ID: 15909786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain].
    Überall MA
    MMW Fortschr Med; 2017 Oct; 159(Suppl 6):15-22. PubMed ID: 29557092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl].
    Yomiya K; Kaneshima M; Kyosaka B; Warita E; Hosonuma R; Osato S
    Gan To Kagaku Ryoho; 2017 Apr; 44(4):289-293. PubMed ID: 28428506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
    Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
    Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.
    Chang A; Roeland EJ; Atayee RS; Revta C; Ma JD
    J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):247-60. PubMed ID: 26368648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of rapid onset fentanyl products in the management of breakthrough pain in cancer patients.
    Brząkała J; Leppert W
    Pharmacol Rep; 2019 Jun; 71(3):438-442. PubMed ID: 31003154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fentanyl: fast and furious?].
    Meissner W; Sabatowski R
    Anaesthesist; 2013 Jun; 62(6):429-30. PubMed ID: 23748418
    [No Abstract]   [Full Text] [Related]  

  • 18. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
    Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
    Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
    Mercadante S; Ferrera P; Adile C; Casuccio A
    J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies.
    Triarico S; Capozza MA; Mastrangelo S; Attinà G; Maurizi P; Ruggiero A
    Support Care Cancer; 2019 Oct; 27(10):3639-3645. PubMed ID: 31154533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.